ArticleDiabetology international2026
Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study.
Article in Diabetology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in preclinical studies; however, its impact on liver function and body composition in MASLD remains unclear. Methods: This retrospective, single-center pilot study analyzed prospectively collected data from 28 patients with MASLD and T2DM who were treated with imeglimin for 6 months. Clinical and biochemical parameters were assessed at baseline and at 3 and 6 months. Body composition was evaluated using bioelectrical impedance analysis. Results: Over 6 months, fasting blood glucose decreased from 148.5 to 131.0 mg/dL ( Conclusion: Imeglimin therapy was associated with favorable changes in glycemic parameters, liver enzymes, and body composition in this pilot cohort, without a statistically significant reduction in skeletal muscle mass. These findings suggest a potential metabolic and hepatic effect of imeglimin and may be particularly relevant for patients with MASLD at risk of sarcopenia. Larger prospective studies with histological or validated non-invasive endpoints are warranted. Graphical abstract: Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13340-026-00931-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.